Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States. The FDA has approved the fifth bevacizumab ...
Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use ...
Bio-Thera Solutions has received the Food and Drug Administration’s green light for Avzivi (bevacizumab-tnjn), which is a biosimilar of Avastin. Avzivi is Bio-Thera's second FDA approved product and ...
The totality of the evidence demonstrated that Avzivi has similar efficacy, safety, and immunogenicity as the reference product. The approval was based on a comprehensive data package that included a ...
On December 7, 2023, Bio-Thera Solutions, Ltd. announced that the FDA has approved AVZIVI (bevacizumab-tnjn), a biosimilar referencing Genentech’s AVASTIN. AVZIZI is the fifth bevacizumab biosimilar ...
is the second biosimilar researched, developed, and manufactured by a Chinese Pharmaceutical company to receive FDA approval in the United States GUANGZHOU, China, Dec. 7, 2023 /PRNewswire/ -- ...
At its May 30 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsed the approval of several cancer therapies. The drug review panel ...
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Avzivi ® to the reference product Avastin ® GUANGZHOU, China, June 3, 2024 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results